false 0001623526 0001623526 2024-06-05 2024-06-05

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

 

 

FORM 8-K

 

 

CURRENT REPORT

Pursuant to Section 13 or 15(d)

of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): June 5, 2024

 

 

Stoke Therapeutics, Inc.

(Exact name of Registrant as Specified in Its Charter)

 

 

 

Delaware   001-38938   47-1144582
(State or Other Jurisdiction
of Incorporation)		   (Commission
File Number)		   (IRS Employer
Identification No.)

 

45 Wiggins Ave  
Bedford, Massachusetts   01730
(Address of Principal Executive Offices)   (Zip Code)

Registrant’s Telephone Number, Including Area Code: (781) 430-8200

Not Applicable

(Former Name or Former Address, if Changed Since Last Report)

 

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

 

☐

Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

 

☐

Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

 

☐

Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

 

☐

Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

 

Title of each class

  

Trading
Symbol(s)

  

Name of each exchange
on which registered

Common Stock, $0.0001 par value per share   STOK   Nasdaq Global Select Market

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).

Emerging growth company ☒

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

 

 

 

Item 5.07

Submission of Matters to a Vote of Security Holders.

On June 5, 2024, Stoke Therapeutics, Inc. (the “Company”) held its 2024 Annual Meeting of Stockholders, and the following proposals were adopted:

 

1.

Election of three Class II directors, Jennifer C. Burstein, Arthur A. Levin, Ph.D. and Ian F. Smith, each to serve a three-year term, which will expire upon the earlier of the 2027 Annual Meeting of Stockholders or until such time as their respective successors have been duly elected and qualified:

 

Nominees

  

Shares For

  

Shares Withheld

  

Broker Non-Votes

Jennifer C. Burstein

   32,396,633   1,970,217   5,561,508

Arthur A. Levin, Ph.D.

   25,556,568   8,810,282   5,561,508

Ian F. Smith

   33,961,032   405,818   5,561,508

 

2.

Ratification of the appointment of KPMG LLP as the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2024:

 

Shares For

  

Shares Against

  

Shares Withheld/Abstaining

39,911,634

   6,826   9,898

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Date: June 6, 2024

 

STOKE THERAPEUTICS, INC.
By:  

/s/ Thomas Leggett

  Thomas Leggett
  Chief Financial Officer
v3.24.1.1.u2
Document and Entity Information
Jun. 05, 2024
Cover [Abstract]  
Amendment Flag false
Entity Central Index Key 0001623526
Document Type 8-K
Document Period End Date Jun. 05, 2024
Entity Registrant Name Stoke Therapeutics, Inc.
Entity Incorporation State Country Code DE
Entity File Number 001-38938
Entity Tax Identification Number 47-1144582
Entity Address, Address Line One 45 Wiggins Ave
Entity Address, City or Town Bedford
Entity Address, State or Province MA
Entity Address, Postal Zip Code 01730
City Area Code (781)
Local Phone Number 430-8200
Written Communications false
Soliciting Material false
Pre Commencement Tender Offer false
Pre Commencement Issuer Tender Offer false
Security 12b Title Common Stock, $0.0001 par value per share
Trading Symbol STOK
Security Exchange Name NASDAQ
Entity Emerging Growth Company true
Entity Ex Transition Period false
Grafico Azioni Stoke Therapeutics (NASDAQ:STOK)
Storico
Da Mag 2024 a Giu 2024 Clicca qui per i Grafici di Stoke Therapeutics
Grafico Azioni Stoke Therapeutics (NASDAQ:STOK)
Storico
Da Giu 2023 a Giu 2024 Clicca qui per i Grafici di Stoke Therapeutics